[Thromboembolic events associated bevacizumab treatment].
Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University.
Shunsuke
S
Kato
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D013923:Thromboembolism / Q000139:chemically induced*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab